Acurx Pharmaceuticals, Inc.

NasdaqCM:ACXP 株式レポート

時価総額:US$19.3m

Acurx Pharmaceuticals マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Dave Luci

最高経営責任者

US$1.0m

報酬総額

CEO給与比率46.4%
CEO在任期間6.8yrs
CEOの所有権6.8%
経営陣の平均在職期間データなし
取締役会の平均在任期間3.3yrs

経営陣の近況

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Aug 11
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30
Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

CEO報酬分析

Acurx Pharmaceuticals の収益と比較して、Dave Luci の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$1mUS$475k

-US$15m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$655kUS$475k

-US$12m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$4mUS$364k

-US$13m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$596kUS$277k

-US$5m

Dec 31 2019US$290kUS$267k

-US$6m

報酬と市場: Daveの 総報酬 ($USD 1.02M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Daveの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Dave Luci (57 yo)

6.8yrs

在職期間

US$1,023,878

報酬

Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...


取締役

名称ポジション在職期間報酬所有権
Robert DeLuccia
Co-Founder & Executive Chairman6.8yrsUS$1.06m5.94%
$ 1.1m
David Luci
Co-Founder6.8yrsUS$1.02m6.76%
$ 1.3m
Joseph Scodari
Independent Director3.3yrsUS$78.94k0.019%
$ 3.6k
Thomas Harrison
Independent Director3.3yrsUS$73.94k0.0095%
$ 1.8k
James Donohue
Independent Director3.3yrsUS$76.44k0.077%
$ 14.8k
Carl Sailer
Independent Director6.1yrsUS$66.44k0.72%
$ 139.4k
Jack Dean
Independent Director & Scientific Advisor3.3yrsUS$61.44k0.11%
$ 21.0k
Richard Ellison
Scientific Advisorno dataデータなしデータなし
Ciaran Kelly
Scientific Advisorno dataデータなしデータなし
Kevin Garey
Scientific Advisorno dataデータなしデータなし
Mark Goldberger
Scientific Advisorno dataデータなしデータなし
Ellie Goldstein
Scientific Advisorno dataデータなしデータなし

3.3yrs

平均在職期間

71yo

平均年齢

経験豊富なボード: ACXPの 取締役会経験豊富 であると考えられます ( 3.3年の平均在任期間)。